بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significance we » significance set (توسيع البحث), significance _ (توسيع البحث), significance b (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significance we » significance set (توسيع البحث), significance _ (توسيع البحث), significance b (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
-
21
-
22
Table 1_Multi-generational adaptation to Solanum nigrum increases reproduction and decreases microbial diversity of Aphis gossypii.docx
منشور في 2025"…The relative abundance of Buchnera in T5 and T10 significantly increased compared to M and T, while the relative abundance of Arsenophonus decreased markedly. …"
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
منشور في 2024"…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …"
-
35
-
36
-
37
-
38
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
39
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
40
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"